Companies
Unlearn.AI
its AI-generated digital twins are increasingly used to power synthetic control arms, and the company published a roadmap on causal inference and digital twins for the future of clinical trials in npj Digital Medicine in June 2026;…
- Country
- United States
Synthetic control arms
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $134.85 million total raised across multiple rounds, including a $50 million Series C in 2024 | businesswire.com |
| Headcount | Approximately 60-76 employees medium confidence | datanyze.com |
| Regulatory approval | European Medicines Agency (EMA) qualified their PROCOVA methodology for Phase 2 and 3 clinical trials; received positive feedback from U.S. FDA on the methodology | casrai.org · businesswire.com · unlearn.ai |
| Capacity | Technology is deployable as a web-based application or as a secure, on-premises solution within a sponsor’s cloud infrastructure medium confidence | unlearn.ai |
| Production site | Digital twin generation platforms deployed within sponsor-controlled secure cloud environments medium confidence | unlearn.ai |
Independent sources: businesswire.com · casrai.org · datanyze.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Patient digital twins & in-silico trials | regenerative-personalized | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.